Business
Result of AGM
Result of AGM.
About this update from Ixico Plc
24 January 2025 IXICO plc ("IXICO" or the "Company") Results of AGM IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows: RESOLUTION VOTES FOR % VOTES AGAINST % VOTES TOTAL % ISC VOTED VOTES WITHHELD 1 Reports and Accounts 68,485,623 99.95% 31,468 0.05% 68,517,091 73.94 400 2a Election of Bram Goorden 68,473,140 99.95% 32,668 0.05% 68,505,808 73.93 11,683 2b Re-election of Grant Nash 68,474,566 99.95% 36,376 0.05% 68,510,942 73.93 6,549 2c Re-election of Mark Warne 68,473,966 99.95% 36,976 0.05% 68,510,942 73.93 6,549 2d Re-election of Dr Dipti Amin 68,470,760 99.95% 35,048 0.05% 68,505,808 73.93 11,683 2e Re-election of Kate Rogers 68,475,894 99.95% 35,048 0.05% 68,510,942 73.93 6,549 3 Re-appointment of Moore Kingston Smith Auditors 68,473,359 99.95% 36,401 0.05% 68,509,760 73.93 7,731 4 Allotment of Securities 68,475,089 99.94% 41,502 0.06% 68,516,591 73.94 900 5 * Disapply Pre-Emption Provisions 68,399,849 99.83% 116,742 0.17% 68,516,591 73.94 900 6 * Issue of 'value multiple and exit' share options to Bram Goorden, CEO, and Grant Nash, CFO. 68,352,128 99.76% 163,273 0.24% 68,515,401 73.94 2,090 7 * To adopt new Articles of Association for the Company 68,473,361 99.94% 43,830 0.06% 68,517,191 73.94 300 * Special Resolutions Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution. Further information: IXICO plc +44 (0) 20 3763 7499 Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) +44 (0) 20 7220 0500 Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) About IXICO www.IXICO.com IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients .